https://compoundevidence.com/comment-periods/draft-certainty-framework-v2/2024-08-04 https://compoundevidence.com/comment-periods/draft-certainty-framework-v2/submissions/2024-08-04 https://compoundevidence.com/comment-periods/draft-certainty-framework-v2/disposition/2024-08-04 https://compoundevidence.com/comment-periods/draft-supplier-rubric/2023-10-22 https://compoundevidence.com/comment-periods/draft-supplier-rubric/submissions/2023-10-22 https://compoundevidence.com/comment-periods/draft-supplier-rubric/disposition/2023-10-22 https://compoundevidence.com/comment-periods/draft-coa-minimum-data-standard/2023-12-12 https://compoundevidence.com/comment-periods/draft-coa-minimum-data-standard/submissions/2023-12-12 https://compoundevidence.com/comment-periods/draft-coa-minimum-data-standard/disposition/2023-12-12 https://compoundevidence.com/comment-periods/draft-rp-hplc-purity-standard/2023-06-30 https://compoundevidence.com/comment-periods/draft-rp-hplc-purity-standard/submissions/2023-06-30 https://compoundevidence.com/comment-periods/draft-rp-hplc-purity-standard/disposition/2023-06-30 https://compoundevidence.com/comment-periods/draft-semaglutide-monograph-v3/2025-04-03 https://compoundevidence.com/comment-periods/draft-semaglutide-monograph-v3/submissions/2025-04-03 https://compoundevidence.com/comment-periods/draft-semaglutide-monograph-v3/disposition/2025-04-03 https://compoundevidence.com/comment-periods/draft-tirzepatide-monograph-v2/2025-07-02 https://compoundevidence.com/comment-periods/draft-tirzepatide-monograph-v2/submissions/2025-07-02 https://compoundevidence.com/comment-periods/draft-tirzepatide-monograph-v2/disposition/2025-07-02 https://compoundevidence.com/comment-periods/draft-bpc-157-monograph/2024-03-31 https://compoundevidence.com/comment-periods/draft-bpc-157-monograph/submissions/2024-03-31 https://compoundevidence.com/comment-periods/draft-bpc-157-monograph/disposition/2024-03-31 https://compoundevidence.com/comment-periods/draft-weight-regain-synthesis/2025-11-05 https://compoundevidence.com/comment-periods/draft-weight-regain-synthesis/submissions/2025-11-05 https://compoundevidence.com/comment-periods/draft-weight-regain-synthesis/disposition/2025-11-05 https://compoundevidence.com/comment-periods/draft-network-transitivity/2026-03-20 https://compoundevidence.com/comment-periods/draft-network-transitivity/submissions/2026-03-20 https://compoundevidence.com/comment-periods/draft-network-transitivity/disposition/2026-03-20 https://compoundevidence.com/comment-periods/draft-conflicts-policy/2023-04-01 https://compoundevidence.com/comment-periods/draft-conflicts-policy/submissions/2023-04-01 https://compoundevidence.com/comment-periods/draft-conflicts-policy/disposition/2023-04-01 https://compoundevidence.com/comment-periods/draft-funding-policy/2023-03-24 https://compoundevidence.com/comment-periods/draft-funding-policy/submissions/2023-03-24 https://compoundevidence.com/comment-periods/draft-funding-policy/disposition/2023-03-24 https://compoundevidence.com/comment-periods/draft-citation-policy/2024-10-05 https://compoundevidence.com/comment-periods/draft-citation-policy/submissions/2024-10-05 https://compoundevidence.com/comment-periods/draft-citation-policy/disposition/2024-10-05 https://compoundevidence.com/comment-periods/draft-programme-record-notice/2025-01-05 https://compoundevidence.com/comment-periods/draft-programme-record-notice/submissions/2025-01-05 https://compoundevidence.com/comment-periods/draft-programme-record-notice/disposition/2025-01-05 https://compoundevidence.com/comment-periods/draft-endotoxin-standard/2025-11-23 https://compoundevidence.com/comment-periods/draft-endotoxin-standard/submissions/2025-11-23 https://compoundevidence.com/comment-periods/draft-endotoxin-standard/disposition/2025-11-23 https://compoundevidence.com/comment-periods/draft-analytical-series-scope/2023-12-28 https://compoundevidence.com/comment-periods/draft-analytical-series-scope/submissions/2023-12-28 https://compoundevidence.com/comment-periods/draft-analytical-series-scope/disposition/2023-12-28 https://compoundevidence.com/comment-periods/draft-glp1-obesity-synthesis-v2/2026-04-13 https://compoundevidence.com/comment-periods/draft-glp1-obesity-synthesis-v2/submissions/2026-04-13 https://compoundevidence.com/comment-periods/draft-glp1-obesity-synthesis-v2/disposition/2026-04-13 https://compoundevidence.com/comment-periods/draft-lean-mass-scoping/2026-07-21 https://compoundevidence.com/comment-periods/draft-lean-mass-scoping/submissions/2026-07-21 https://compoundevidence.com/comment-periods/draft-lean-mass-scoping/disposition/2026-07-21 https://compoundevidence.com/comment-periods/draft-gastroparesis-safety-review/2025-12-26 https://compoundevidence.com/comment-periods/draft-gastroparesis-safety-review/submissions/2025-12-26 https://compoundevidence.com/comment-periods/draft-gastroparesis-safety-review/disposition/2025-12-26 https://compoundevidence.com/comment-periods/draft-thyroid-c-cell-review/2025-06-13 https://compoundevidence.com/comment-periods/draft-thyroid-c-cell-review/submissions/2025-06-13 https://compoundevidence.com/comment-periods/draft-thyroid-c-cell-review/disposition/2025-06-13 https://compoundevidence.com/comment-periods/draft-supplier-dossier-format/2024-04-11 https://compoundevidence.com/comment-periods/draft-supplier-dossier-format/submissions/2024-04-11 https://compoundevidence.com/comment-periods/draft-supplier-dossier-format/disposition/2024-04-11 https://compoundevidence.com/comment-periods/draft-people-register-policy/2024-07-10 https://compoundevidence.com/comment-periods/draft-people-register-policy/submissions/2024-07-10 https://compoundevidence.com/comment-periods/draft-people-register-policy/disposition/2024-07-10 https://compoundevidence.com/comment-periods/draft-corrections-policy/2024-09-06 https://compoundevidence.com/comment-periods/draft-corrections-policy/submissions/2024-09-06 https://compoundevidence.com/comment-periods/draft-corrections-policy/disposition/2024-09-06 https://compoundevidence.com/comment-periods/draft-stability-standard/2026-06-26 https://compoundevidence.com/comment-periods/draft-stability-standard/submissions/2026-06-26 https://compoundevidence.com/comment-periods/draft-stability-standard/disposition/2026-06-26 https://compoundevidence.com/comment-periods/draft-indication-set/2023-10-08 https://compoundevidence.com/comment-periods/draft-indication-set/submissions/2023-10-08 https://compoundevidence.com/comment-periods/draft-indication-set/disposition/2023-10-08 https://compoundevidence.com/comment-periods/draft-mash-synthesis/2026-07-12 https://compoundevidence.com/comment-periods/draft-mash-synthesis/submissions/2026-07-12 https://compoundevidence.com/comment-periods/draft-mash-synthesis/disposition/2026-07-12 https://compoundevidence.com/comment-periods/draft-adolescent-synthesis/2026-04-24 https://compoundevidence.com/comment-periods/draft-adolescent-synthesis/submissions/2026-04-24 https://compoundevidence.com/comment-periods/draft-adolescent-synthesis/disposition/2026-04-24 https://compoundevidence.com/comment-periods/draft-analytical-survey-review/2025-09-24 https://compoundevidence.com/comment-periods/draft-analytical-survey-review/submissions/2025-09-24 https://compoundevidence.com/comment-periods/draft-analytical-survey-review/disposition/2025-09-24 https://compoundevidence.com/comment-periods/draft-registry-structure/2025-01-10 https://compoundevidence.com/comment-periods/draft-registry-structure/submissions/2025-01-10 https://compoundevidence.com/comment-periods/draft-registry-structure/disposition/2025-01-10 https://compoundevidence.com/comment-periods/draft-tools-disclaimer/2025-05-01 https://compoundevidence.com/comment-periods/draft-tools-disclaimer/submissions/2025-05-01 https://compoundevidence.com/comment-periods/draft-tools-disclaimer/disposition/2025-05-01 https://compoundevidence.com/comment-periods/draft-orforglipron-monograph/2026-07-06 https://compoundevidence.com/comment-periods/draft-orforglipron-monograph/submissions/2026-07-06 https://compoundevidence.com/comment-periods/draft-orforglipron-monograph/disposition/2026-07-06 https://compoundevidence.com/comment-periods/draft-danuglipron-monograph/2025-09-16 https://compoundevidence.com/comment-periods/draft-danuglipron-monograph/submissions/2025-09-16 https://compoundevidence.com/comment-periods/draft-danuglipron-monograph/disposition/2025-09-16 https://compoundevidence.com/comment-periods/draft-methodology-v4/2026-07-31 https://compoundevidence.com/comment-periods/draft-methodology-v4/submissions/2026-07-31 https://compoundevidence.com/comment-periods/draft-methodology-v4/disposition/2026-07-31 https://compoundevidence.com/comment-periods/draft-suppliers-comparison-table/2025-06-10 https://compoundevidence.com/comment-periods/draft-suppliers-comparison-table/submissions/2025-06-10 https://compoundevidence.com/comment-periods/draft-suppliers-comparison-table/disposition/2025-06-10 https://compoundevidence.com/comment-periods/draft-retatrutide-monograph/2026-03-25 https://compoundevidence.com/comment-periods/draft-retatrutide-monograph/submissions/2026-03-25 https://compoundevidence.com/comment-periods/draft-retatrutide-monograph/disposition/2026-03-25 https://compoundevidence.com/comment-periods/draft-melanocortin-review/2026-01-16 https://compoundevidence.com/comment-periods/draft-melanocortin-review/submissions/2026-01-16 https://compoundevidence.com/comment-periods/draft-melanocortin-review/disposition/2026-01-16 https://compoundevidence.com/comment-periods/draft-search-strategy-template/2025-01-13 https://compoundevidence.com/comment-periods/draft-search-strategy-template/submissions/2025-01-13 https://compoundevidence.com/comment-periods/draft-search-strategy-template/disposition/2025-01-13 https://compoundevidence.com/comment-periods/draft-print-and-archival-format/2025-05-02 https://compoundevidence.com/comment-periods/draft-print-and-archival-format/submissions/2025-05-02 https://compoundevidence.com/comment-periods/draft-print-and-archival-format/disposition/2025-05-02 https://compoundevidence.com/comment-periods/draft-certainty-index/2026-07-10 https://compoundevidence.com/comment-periods/draft-certainty-index/submissions/2026-07-10 https://compoundevidence.com/comment-periods/draft-certainty-index/disposition/2026-07-10 https://compoundevidence.com/comment-periods/draft-amycretin-monograph/2026-08-05 https://compoundevidence.com/comment-periods/draft-amycretin-monograph/submissions/2026-08-05 https://compoundevidence.com/comment-periods/draft-amycretin-monograph/disposition/2026-08-05 https://compoundevidence.com/comment-periods/draft-5-amino-1mq-monograph/2026-04-23 https://compoundevidence.com/comment-periods/draft-5-amino-1mq-monograph/submissions/2026-04-23 https://compoundevidence.com/comment-periods/draft-5-amino-1mq-monograph/disposition/2026-04-23 https://compoundevidence.com/comment-periods/draft-aod-9604-monograph/2024-09-25 https://compoundevidence.com/comment-periods/draft-aod-9604-monograph/submissions/2024-09-25 https://compoundevidence.com/comment-periods/draft-aod-9604-monograph/disposition/2024-09-25 https://compoundevidence.com/comment-periods/draft-cagrilintide-monograph/2024-03-29 https://compoundevidence.com/comment-periods/draft-cagrilintide-monograph/submissions/2024-03-29 https://compoundevidence.com/comment-periods/draft-cagrilintide-monograph/disposition/2024-03-29 https://compoundevidence.com/comment-periods/draft-cagrisema-monograph/2025-10-22 https://compoundevidence.com/comment-periods/draft-cagrisema-monograph/submissions/2025-10-22 https://compoundevidence.com/comment-periods/draft-cagrisema-monograph/disposition/2025-10-22 https://compoundevidence.com/comment-periods/draft-cjc-1295-monograph/2026-07-21 https://compoundevidence.com/comment-periods/draft-cjc-1295-monograph/submissions/2026-07-21 https://compoundevidence.com/comment-periods/draft-cjc-1295-monograph/disposition/2026-07-21 https://compoundevidence.com/comment-periods/draft-dsip-monograph/2025-09-14 https://compoundevidence.com/comment-periods/draft-dsip-monograph/submissions/2025-09-14 https://compoundevidence.com/comment-periods/draft-dsip-monograph/disposition/2025-09-14 https://compoundevidence.com/comment-periods/draft-dulaglutide-monograph/2025-03-14 https://compoundevidence.com/comment-periods/draft-dulaglutide-monograph/submissions/2025-03-14 https://compoundevidence.com/comment-periods/draft-dulaglutide-monograph/disposition/2025-03-14 https://compoundevidence.com/comment-periods/draft-ecnoglutide-monograph/2026-04-05 https://compoundevidence.com/comment-periods/draft-ecnoglutide-monograph/submissions/2026-04-05 https://compoundevidence.com/comment-periods/draft-ecnoglutide-monograph/disposition/2026-04-05 https://compoundevidence.com/comment-periods/draft-epithalon-monograph/2026-02-16 https://compoundevidence.com/comment-periods/draft-epithalon-monograph/submissions/2026-02-16 https://compoundevidence.com/comment-periods/draft-epithalon-monograph/disposition/2026-02-16 https://compoundevidence.com/comment-periods/draft-exenatide-monograph/2026-08-07 https://compoundevidence.com/comment-periods/draft-exenatide-monograph/submissions/2026-08-07 https://compoundevidence.com/comment-periods/draft-exenatide-monograph/disposition/2026-08-07 https://compoundevidence.com/comment-periods/draft-ghk-cu-monograph/2025-02-27 https://compoundevidence.com/comment-periods/draft-ghk-cu-monograph/submissions/2025-02-27 https://compoundevidence.com/comment-periods/draft-ghk-cu-monograph/disposition/2025-02-27 https://compoundevidence.com/comment-periods/draft-ghrp-2-monograph/2025-03-30 https://compoundevidence.com/comment-periods/draft-ghrp-2-monograph/submissions/2025-03-30 https://compoundevidence.com/comment-periods/draft-ghrp-2-monograph/disposition/2025-03-30 https://compoundevidence.com/comment-periods/draft-ghrp-6-monograph/2024-05-01 https://compoundevidence.com/comment-periods/draft-ghrp-6-monograph/submissions/2024-05-01 https://compoundevidence.com/comment-periods/draft-ghrp-6-monograph/disposition/2024-05-01 https://compoundevidence.com/comment-periods/draft-glutathione-monograph/2024-03-29 https://compoundevidence.com/comment-periods/draft-glutathione-monograph/submissions/2024-03-29 https://compoundevidence.com/comment-periods/draft-glutathione-monograph/disposition/2024-03-29 https://compoundevidence.com/comment-periods/draft-gonadorelin-monograph/2024-09-08 https://compoundevidence.com/comment-periods/draft-gonadorelin-monograph/submissions/2024-09-08 https://compoundevidence.com/comment-periods/draft-gonadorelin-monograph/disposition/2024-09-08 https://compoundevidence.com/comment-periods/draft-hexarelin-monograph/2024-08-27 https://compoundevidence.com/comment-periods/draft-hexarelin-monograph/submissions/2024-08-27 https://compoundevidence.com/comment-periods/draft-hexarelin-monograph/disposition/2024-08-27 https://compoundevidence.com/comment-periods/draft-igf-1-lr3-monograph/2024-07-07 https://compoundevidence.com/comment-periods/draft-igf-1-lr3-monograph/submissions/2024-07-07 https://compoundevidence.com/comment-periods/draft-igf-1-lr3-monograph/disposition/2024-07-07 https://compoundevidence.com/comment-periods/draft-ipamorelin-monograph/2025-11-23 https://compoundevidence.com/comment-periods/draft-ipamorelin-monograph/submissions/2025-11-23 https://compoundevidence.com/comment-periods/draft-ipamorelin-monograph/disposition/2025-11-23 https://compoundevidence.com/comment-periods/draft-kisspeptin-10-monograph/2024-08-10 https://compoundevidence.com/comment-periods/draft-kisspeptin-10-monograph/submissions/2024-08-10 https://compoundevidence.com/comment-periods/draft-kisspeptin-10-monograph/disposition/2024-08-10 https://compoundevidence.com/comment-periods/draft-kpv-monograph/2026-07-02 https://compoundevidence.com/comment-periods/draft-kpv-monograph/submissions/2026-07-02 https://compoundevidence.com/comment-periods/draft-kpv-monograph/disposition/2026-07-02 https://compoundevidence.com/comment-periods/draft-larazotide-monograph/2024-10-16 https://compoundevidence.com/comment-periods/draft-larazotide-monograph/submissions/2024-10-16 https://compoundevidence.com/comment-periods/draft-larazotide-monograph/disposition/2024-10-16 https://compoundevidence.com/comment-periods/draft-liraglutide-monograph/2025-09-06 https://compoundevidence.com/comment-periods/draft-liraglutide-monograph/submissions/2025-09-06 https://compoundevidence.com/comment-periods/draft-liraglutide-monograph/disposition/2025-09-06 https://compoundevidence.com/comment-periods/draft-lixisenatide-monograph/2026-06-06 https://compoundevidence.com/comment-periods/draft-lixisenatide-monograph/submissions/2026-06-06 https://compoundevidence.com/comment-periods/draft-lixisenatide-monograph/disposition/2026-06-06 https://compoundevidence.com/comment-periods/draft-ll-37-monograph/2024-07-05 https://compoundevidence.com/comment-periods/draft-ll-37-monograph/submissions/2024-07-05 https://compoundevidence.com/comment-periods/draft-ll-37-monograph/disposition/2024-07-05 https://compoundevidence.com/comment-periods/draft-maridebart-cafraglutide-monograph/2024-03-21 https://compoundevidence.com/comment-periods/draft-maridebart-cafraglutide-monograph/submissions/2024-03-21 https://compoundevidence.com/comment-periods/draft-maridebart-cafraglutide-monograph/disposition/2024-03-21 https://compoundevidence.com/comment-periods/draft-mazdutide-monograph/2026-01-25 https://compoundevidence.com/comment-periods/draft-mazdutide-monograph/submissions/2026-01-25 https://compoundevidence.com/comment-periods/draft-mazdutide-monograph/disposition/2026-01-25 https://compoundevidence.com/comment-periods/draft-melanotan-ii-monograph/2026-03-05 https://compoundevidence.com/comment-periods/draft-melanotan-ii-monograph/submissions/2026-03-05 https://compoundevidence.com/comment-periods/draft-melanotan-ii-monograph/disposition/2026-03-05 https://compoundevidence.com/comment-periods/draft-mots-c-monograph/2026-07-15 https://compoundevidence.com/comment-periods/draft-mots-c-monograph/submissions/2026-07-15 https://compoundevidence.com/comment-periods/draft-mots-c-monograph/disposition/2026-07-15 https://compoundevidence.com/comment-periods/draft-nad-plus-monograph/2025-09-29 https://compoundevidence.com/comment-periods/draft-nad-plus-monograph/submissions/2025-09-29 https://compoundevidence.com/comment-periods/draft-nad-plus-monograph/disposition/2025-09-29 https://compoundevidence.com/comment-periods/draft-oral-semaglutide-monograph/2024-12-30 https://compoundevidence.com/comment-periods/draft-oral-semaglutide-monograph/submissions/2024-12-30 https://compoundevidence.com/comment-periods/draft-oral-semaglutide-monograph/disposition/2024-12-30 https://compoundevidence.com/comment-periods/draft-petrelintide-monograph/2024-06-20 https://compoundevidence.com/comment-periods/draft-petrelintide-monograph/submissions/2024-06-20 https://compoundevidence.com/comment-periods/draft-petrelintide-monograph/disposition/2024-06-20 https://compoundevidence.com/comment-periods/draft-pramlintide-monograph/2026-06-30 https://compoundevidence.com/comment-periods/draft-pramlintide-monograph/submissions/2026-06-30 https://compoundevidence.com/comment-periods/draft-pramlintide-monograph/disposition/2026-06-30 https://compoundevidence.com/comment-periods/draft-pt-141-monograph/2026-06-30 https://compoundevidence.com/comment-periods/draft-pt-141-monograph/submissions/2026-06-30 https://compoundevidence.com/comment-periods/draft-pt-141-monograph/disposition/2026-06-30 https://compoundevidence.com/comment-periods/draft-selank-monograph/2025-06-22 https://compoundevidence.com/comment-periods/draft-selank-monograph/submissions/2025-06-22 https://compoundevidence.com/comment-periods/draft-selank-monograph/disposition/2025-06-22 https://compoundevidence.com/comment-periods/draft-semax-monograph/2025-10-14 https://compoundevidence.com/comment-periods/draft-semax-monograph/submissions/2025-10-14 https://compoundevidence.com/comment-periods/draft-semax-monograph/disposition/2025-10-14 https://compoundevidence.com/comment-periods/draft-sermorelin-monograph/2026-07-03 https://compoundevidence.com/comment-periods/draft-sermorelin-monograph/submissions/2026-07-03 https://compoundevidence.com/comment-periods/draft-sermorelin-monograph/disposition/2026-07-03 https://compoundevidence.com/comment-periods/draft-ss-31-monograph/2026-07-04 https://compoundevidence.com/comment-periods/draft-ss-31-monograph/submissions/2026-07-04 https://compoundevidence.com/comment-periods/draft-ss-31-monograph/disposition/2026-07-04 https://compoundevidence.com/comment-periods/draft-survodutide-monograph/2024-12-10 https://compoundevidence.com/comment-periods/draft-survodutide-monograph/submissions/2024-12-10 https://compoundevidence.com/comment-periods/draft-survodutide-monograph/disposition/2024-12-10 https://compoundevidence.com/comment-periods/draft-tb-500-monograph/2025-05-22 https://compoundevidence.com/comment-periods/draft-tb-500-monograph/submissions/2025-05-22 https://compoundevidence.com/comment-periods/draft-tb-500-monograph/disposition/2025-05-22 https://compoundevidence.com/comment-periods/draft-teduglutide-monograph/2024-03-05 https://compoundevidence.com/comment-periods/draft-teduglutide-monograph/submissions/2024-03-05 https://compoundevidence.com/comment-periods/draft-teduglutide-monograph/disposition/2024-03-05 https://compoundevidence.com/comment-periods/draft-tesamorelin-monograph/2025-09-28 https://compoundevidence.com/comment-periods/draft-tesamorelin-monograph/submissions/2025-09-28 https://compoundevidence.com/comment-periods/draft-tesamorelin-monograph/disposition/2025-09-28 https://compoundevidence.com/comment-periods/draft-thymalin-monograph/2025-10-25 https://compoundevidence.com/comment-periods/draft-thymalin-monograph/submissions/2025-10-25 https://compoundevidence.com/comment-periods/draft-thymalin-monograph/disposition/2025-10-25 https://compoundevidence.com/comment-periods/draft-thymosin-alpha-1-monograph/2024-11-13 https://compoundevidence.com/comment-periods/draft-thymosin-alpha-1-monograph/submissions/2024-11-13 https://compoundevidence.com/comment-periods/draft-thymosin-alpha-1-monograph/disposition/2024-11-13 https://compoundevidence.com/comment-periods/draft-thymosin-beta-4-monograph/2026-03-29 https://compoundevidence.com/comment-periods/draft-thymosin-beta-4-monograph/submissions/2026-03-29 https://compoundevidence.com/comment-periods/draft-thymosin-beta-4-monograph/disposition/2026-03-29 https://compoundevidence.com/comment-periods/draft-lcmsms-identity-standard/2024-03-21 https://compoundevidence.com/comment-periods/draft-lcmsms-identity-standard/submissions/2024-03-21 https://compoundevidence.com/comment-periods/draft-lcmsms-identity-standard/disposition/2024-03-21 https://compoundevidence.com/comment-periods/draft-peptide-content-standard/2024-06-24 https://compoundevidence.com/comment-periods/draft-peptide-content-standard/submissions/2024-06-24 https://compoundevidence.com/comment-periods/draft-peptide-content-standard/disposition/2024-06-24 https://compoundevidence.com/comment-periods/draft-water-karl-fischer-standard/2026-06-05 https://compoundevidence.com/comment-periods/draft-water-karl-fischer-standard/submissions/2026-06-05 https://compoundevidence.com/comment-periods/draft-water-karl-fischer-standard/disposition/2026-06-05 https://compoundevidence.com/comment-periods/draft-sterility-usp71-standard/2025-04-14 https://compoundevidence.com/comment-periods/draft-sterility-usp71-standard/submissions/2025-04-14 https://compoundevidence.com/comment-periods/draft-sterility-usp71-standard/disposition/2025-04-14 https://compoundevidence.com/comment-periods/draft-particulate-usp788-standard/2026-07-21 https://compoundevidence.com/comment-periods/draft-particulate-usp788-standard/submissions/2026-07-21 https://compoundevidence.com/comment-periods/draft-particulate-usp788-standard/disposition/2026-07-21 https://compoundevidence.com/comment-periods/draft-related-substances-standard/2026-01-26 https://compoundevidence.com/comment-periods/draft-related-substances-standard/submissions/2026-01-26 https://compoundevidence.com/comment-periods/draft-related-substances-standard/disposition/2026-01-26 https://compoundevidence.com/comment-periods/draft-counter-ion-standard/2024-12-28 https://compoundevidence.com/comment-periods/draft-counter-ion-standard/submissions/2024-12-28 https://compoundevidence.com/comment-periods/draft-counter-ion-standard/disposition/2024-12-28 https://compoundevidence.com/comment-periods/draft-aggregates-sec-standard/2026-02-26 https://compoundevidence.com/comment-periods/draft-aggregates-sec-standard/submissions/2026-02-26 https://compoundevidence.com/comment-periods/draft-aggregates-sec-standard/disposition/2026-02-26 https://compoundevidence.com/comment-periods/draft-residual-solvents-standard/2025-09-29 https://compoundevidence.com/comment-periods/draft-residual-solvents-standard/submissions/2025-09-29 https://compoundevidence.com/comment-periods/draft-residual-solvents-standard/disposition/2025-09-29 https://compoundevidence.com/comment-periods/draft-stability-indicating-standard/2026-07-04 https://compoundevidence.com/comment-periods/draft-stability-indicating-standard/submissions/2026-07-04 https://compoundevidence.com/comment-periods/draft-stability-indicating-standard/disposition/2026-07-04 https://compoundevidence.com/comment-periods/draft-third-party-protocol-standard/2024-06-27 https://compoundevidence.com/comment-periods/draft-third-party-protocol-standard/submissions/2024-06-27 https://compoundevidence.com/comment-periods/draft-third-party-protocol-standard/disposition/2024-06-27 https://compoundevidence.com/comment-periods/draft-appearance-solubility-standard/2025-06-24 https://compoundevidence.com/comment-periods/draft-appearance-solubility-standard/submissions/2025-06-24 https://compoundevidence.com/comment-periods/draft-appearance-solubility-standard/disposition/2025-06-24 https://compoundevidence.com/comment-periods/draft-poorly-retained-standard/2026-04-13 https://compoundevidence.com/comment-periods/draft-poorly-retained-standard/submissions/2026-04-13 https://compoundevidence.com/comment-periods/draft-poorly-retained-standard/disposition/2026-04-13 https://compoundevidence.com/comment-periods/draft-photostability-standard/2026-07-26 https://compoundevidence.com/comment-periods/draft-photostability-standard/submissions/2026-07-26 https://compoundevidence.com/comment-periods/draft-photostability-standard/disposition/2026-07-26 https://compoundevidence.com/comment-periods/draft-dual-vs-single-agonist-weight-synthesis/2026-03-23 https://compoundevidence.com/comment-periods/draft-dual-vs-single-agonist-weight-synthesis/submissions/2026-03-23 https://compoundevidence.com/comment-periods/draft-dual-vs-single-agonist-weight-synthesis/disposition/2026-03-23 https://compoundevidence.com/comment-periods/draft-incretin-cardiovascular-outcomes-synthesis/2025-04-20 https://compoundevidence.com/comment-periods/draft-incretin-cardiovascular-outcomes-synthesis/submissions/2025-04-20 https://compoundevidence.com/comment-periods/draft-incretin-cardiovascular-outcomes-synthesis/disposition/2025-04-20 https://compoundevidence.com/comment-periods/draft-gastrointestinal-tolerability-incretins-synthesis/2025-03-29 https://compoundevidence.com/comment-periods/draft-gastrointestinal-tolerability-incretins-synthesis/submissions/2025-03-29 https://compoundevidence.com/comment-periods/draft-gastrointestinal-tolerability-incretins-synthesis/disposition/2025-03-29 https://compoundevidence.com/comment-periods/draft-oral-vs-injectable-glp1-synthesis/2024-10-10 https://compoundevidence.com/comment-periods/draft-oral-vs-injectable-glp1-synthesis/submissions/2024-10-10 https://compoundevidence.com/comment-periods/draft-oral-vs-injectable-glp1-synthesis/disposition/2024-10-10 https://compoundevidence.com/comment-periods/draft-renal-outcomes-incretins-synthesis/2025-01-17 https://compoundevidence.com/comment-periods/draft-renal-outcomes-incretins-synthesis/submissions/2025-01-17 https://compoundevidence.com/comment-periods/draft-renal-outcomes-incretins-synthesis/disposition/2025-01-17 https://compoundevidence.com/comment-periods/draft-hfpef-incretins-synthesis/2024-03-11 https://compoundevidence.com/comment-periods/draft-hfpef-incretins-synthesis/submissions/2024-03-11 https://compoundevidence.com/comment-periods/draft-hfpef-incretins-synthesis/disposition/2024-03-11 https://compoundevidence.com/comment-periods/draft-sleep-apnoea-weight-agents-synthesis/2024-12-05 https://compoundevidence.com/comment-periods/draft-sleep-apnoea-weight-agents-synthesis/submissions/2024-12-05 https://compoundevidence.com/comment-periods/draft-sleep-apnoea-weight-agents-synthesis/disposition/2024-12-05 https://compoundevidence.com/comment-periods/draft-coa-completeness-research-supply-synthesis/2025-12-12 https://compoundevidence.com/comment-periods/draft-coa-completeness-research-supply-synthesis/submissions/2025-12-12 https://compoundevidence.com/comment-periods/draft-coa-completeness-research-supply-synthesis/disposition/2025-12-12 https://compoundevidence.com/comment-periods/draft-counterion-content-underreporting-synthesis/2024-09-01 https://compoundevidence.com/comment-periods/draft-counterion-content-underreporting-synthesis/submissions/2024-09-01 https://compoundevidence.com/comment-periods/draft-counterion-content-underreporting-synthesis/disposition/2024-09-01 https://compoundevidence.com/comment-periods/draft-bpc-157-human-evidence-synthesis/2025-04-22 https://compoundevidence.com/comment-periods/draft-bpc-157-human-evidence-synthesis/submissions/2025-04-22 https://compoundevidence.com/comment-periods/draft-bpc-157-human-evidence-synthesis/disposition/2025-04-22 https://compoundevidence.com/comment-periods/draft-gh-secretagogue-clinical-evidence-synthesis/2026-01-13 https://compoundevidence.com/comment-periods/draft-gh-secretagogue-clinical-evidence-synthesis/submissions/2026-01-13 https://compoundevidence.com/comment-periods/draft-gh-secretagogue-clinical-evidence-synthesis/disposition/2026-01-13 https://compoundevidence.com/comment-periods/draft-russian-registered-neuropeptides-synthesis/2025-01-06 https://compoundevidence.com/comment-periods/draft-russian-registered-neuropeptides-synthesis/submissions/2025-01-06 https://compoundevidence.com/comment-periods/draft-russian-registered-neuropeptides-synthesis/disposition/2025-01-06 https://compoundevidence.com/comment-periods/draft-sponsor-conducted-evidence-base-synthesis/2024-10-18 https://compoundevidence.com/comment-periods/draft-sponsor-conducted-evidence-base-synthesis/submissions/2024-10-18 https://compoundevidence.com/comment-periods/draft-sponsor-conducted-evidence-base-synthesis/disposition/2024-10-18 https://compoundevidence.com/comment-periods/draft-surrogate-outcomes-in-obesity-synthesis/2025-06-03 https://compoundevidence.com/comment-periods/draft-surrogate-outcomes-in-obesity-synthesis/submissions/2025-06-03 https://compoundevidence.com/comment-periods/draft-surrogate-outcomes-in-obesity-synthesis/disposition/2025-06-03 https://compoundevidence.com/comment-periods/draft-amylin-analogue-evidence-synthesis/2024-09-26 https://compoundevidence.com/comment-periods/draft-amylin-analogue-evidence-synthesis/submissions/2024-09-26 https://compoundevidence.com/comment-periods/draft-amylin-analogue-evidence-synthesis/disposition/2024-09-26 https://compoundevidence.com/comment-periods/draft-discontinued-programmes-as-evidence-synthesis/2026-03-01 https://compoundevidence.com/comment-periods/draft-discontinued-programmes-as-evidence-synthesis/submissions/2026-03-01 https://compoundevidence.com/comment-periods/draft-discontinued-programmes-as-evidence-synthesis/disposition/2026-03-01 https://compoundevidence.com/comment-periods/draft-reconstitution-practice-and-content-synthesis/2026-03-27 https://compoundevidence.com/comment-periods/draft-reconstitution-practice-and-content-synthesis/submissions/2026-03-27 https://compoundevidence.com/comment-periods/draft-reconstitution-practice-and-content-synthesis/disposition/2026-03-27 https://compoundevidence.com/comment-periods/draft-pancreatitis-risk-incretins-synthesis/2025-01-04 https://compoundevidence.com/comment-periods/draft-pancreatitis-risk-incretins-synthesis/submissions/2025-01-04 https://compoundevidence.com/comment-periods/draft-pancreatitis-risk-incretins-synthesis/disposition/2025-01-04 https://compoundevidence.com/comment-periods/draft-endotoxin-in-research-supply-synthesis/2026-08-10 https://compoundevidence.com/comment-periods/draft-endotoxin-in-research-supply-synthesis/submissions/2026-08-10 https://compoundevidence.com/comment-periods/draft-endotoxin-in-research-supply-synthesis/disposition/2026-08-10 https://compoundevidence.com/comment-periods/draft-primary-vs-secondary-prevention-cv-synthesis/2024-06-19 https://compoundevidence.com/comment-periods/draft-primary-vs-secondary-prevention-cv-synthesis/submissions/2024-06-19 https://compoundevidence.com/comment-periods/draft-primary-vs-secondary-prevention-cv-synthesis/disposition/2024-06-19 https://compoundevidence.com/comment-periods/draft-tirzepatide-vs-semaglutide-t2d-synthesis/2025-04-16 https://compoundevidence.com/comment-periods/draft-tirzepatide-vs-semaglutide-t2d-synthesis/submissions/2025-04-16 https://compoundevidence.com/comment-periods/draft-tirzepatide-vs-semaglutide-t2d-synthesis/disposition/2025-04-16 https://compoundevidence.com/comment-periods/draft-peptide-purity-method-dependence-synthesis/2026-07-19 https://compoundevidence.com/comment-periods/draft-peptide-purity-method-dependence-synthesis/submissions/2026-07-19 https://compoundevidence.com/comment-periods/draft-peptide-purity-method-dependence-synthesis/disposition/2026-07-19 https://compoundevidence.com/comment-periods/draft-mitochondrial-peptide-evidence-synthesis/2026-07-14 https://compoundevidence.com/comment-periods/draft-mitochondrial-peptide-evidence-synthesis/submissions/2026-07-14 https://compoundevidence.com/comment-periods/draft-mitochondrial-peptide-evidence-synthesis/disposition/2026-07-14